Skip to content

Translational Research for Persons with Abnormal DNA Damage Response

Translational Research for Persons with Abnormal DNA Damage Response - ADDRess

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00021039
Enrollment
200
Registered
2020-04-28
Start date
2020-03-08
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fanconi anemia Li-Fraumeni-Syndrome Ataxia Teleangiectasia Bloom Syndrome DNA Ligase IV Deficiency Constitutional Mismatch Repair Deficiency Nijmegen Breakage Syndrome Rothmund-Thomson Syndrome Werner Syndrome Xeroderma Pigmentosum Dyskeratosis congenita

Interventions

Group 1: Over an initial period of three years, blood, bone marrow, DNA from buccal swabs, skin or fibroblasts and tumour material will be collected and made available to the various subprojects for t

Sponsors

Pädiatrische Hämatologie und OnkologieMedizinische Hochschule Hannover
Lead Sponsor

Eligibility

Sex/Gender
All
Age
0 Years to 120 Years

Inclusion criteria

Inclusion criteria: - Diagnosis of a cancer predisposition syndrome with underlying DNA repair defect - or: Related person (relative, partner, close person of an LFS victim) - Existence of a written consent to participate in the study

Exclusion criteria

Exclusion criteria: Lack of consent, inability to consent

Design outcomes

Primary

MeasureTime frame
Development of cancer, development of non-malignant complications, physical abnormalities, death

Secondary

MeasureTime frame
- Creation of an infrastructure that facilitates the exchange of information, coordination of consultation and input of medical patient data for patients and medical professionals. - Investigation of the molecular causes of diseases with DNA repair defects. - Promote psychosocial support in an evidence-based way. - Improve early cancer detection through MRI imaging. - Identification of genetic traits in patients with DNA repair defects. - Developing preclinical models to find new therapies for patients with DNA repair defect associated cancer that can be tested in early clinical trials.

Countries

Germany

Contacts

Public ContactChristian Kratz

Medizinische Hochschule HannoverZentrum für Kinderheilkunde und JugendmedizinKlinik für Pädiatrische Hämatologie und Onkologie

kratz.christian@mh-hannover.de+49 (0)511 532-9408

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 27, 2026